Warning letter
AQ USA Inc., d.b.a Ross Healthcare Inc.: warning letter of Feb 12, 2026
FDA warning letter 719517 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 719517 |
|---|---|
| Company | AQ USA Inc., d.b.a Ross Healthcare Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 12, 2026 |
| Posted date | Feb 24, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.160(b), 211.165(b), 211.165(e), 211.188(b), 211.166(a), 211.22, 211.34, 211.80(a), 211.84(d)(1), 211.100(a) |
| Inspection city | Lynden |
| Inspection ZIP | 98264 |
| Inspection start date | Jul 30, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: